Dexedrine
NDC Package 0007-3513-59

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Dexedrine is a medication used to treat attention deficit hyperactivity disorder - ADHD. Marketed by Glaxosmithkline Llc, this product is identified by NDC 0007-3513 and is authorized under FDA application NDA017078.

Identification & Billing

NDC Package Code
0007-3513-59
Package Description
90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
Product Code
0007-3513
11-Digit Billing Format
00007351359

Clinical Specifications

Proprietary Name
Dexedrine
Dosage Form
-
Usage Information
This medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills. This drug is also used to treat a certain sleeping disorder (narcolepsy) to help you stay awake during the day. It should not be used to treat tiredness or to hold off sleep in people who do not have a sleep disorder.

Regulatory & Marketing

Labeler Name
Glaxosmithkline Llc
FDA Application #
NDA017078
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-05-2007
End Marketing Date
01-31-2013
Listing Expiration
01-31-2013
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0007-3513-59 identifies a specific commercial package of 90 capsule, extended release in 1 bottle of Dexedrine, labeled by Glaxosmithkline Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Glaxosmithkline Llc on October 05, 2007. The current certification is valid through January 31, 2013.

What are the primary indications for this medication?

This medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills. This drug is also used to treat a certain sleeping disorder (narcolepsy) to help you stay awake during the day. It should not be used to treat tiredness or to hold off sleep in people who do not have a sleep disorder.

How is this Glaxosmithkline Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00007351359. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0007-3513-59
11-Digit CMS (5-4-2)
00007-3513-59

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.